ES2952774T3 - 1,2,4-triazoles como moduladores del transporte nuclear y uso en el tratamiento de formas específicas de cáncer - Google Patents

1,2,4-triazoles como moduladores del transporte nuclear y uso en el tratamiento de formas específicas de cáncer Download PDF

Info

Publication number
ES2952774T3
ES2952774T3 ES18202641T ES18202641T ES2952774T3 ES 2952774 T3 ES2952774 T3 ES 2952774T3 ES 18202641 T ES18202641 T ES 18202641T ES 18202641 T ES18202641 T ES 18202641T ES 2952774 T3 ES2952774 T3 ES 2952774T3
Authority
ES
Spain
Prior art keywords
compound
cancer
use according
trifluoromethyl
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18202641T
Other languages
English (en)
Spanish (es)
Inventor
Erkan Baloglu
Sharon Shacham
Dilara Mccauley
Trinayan Kashyap
William Senapedis
Yosef Landesman
Gali Golan
Ori Kalid
Sharon Shechter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karyopharm Therapeutics Inc
Original Assignee
Karyopharm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc
Application granted granted Critical
Publication of ES2952774T3 publication Critical patent/ES2952774T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES18202641T 2013-06-21 2014-06-20 1,2,4-triazoles como moduladores del transporte nuclear y uso en el tratamiento de formas específicas de cáncer Active ES2952774T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361838172P 2013-06-21 2013-06-21

Publications (1)

Publication Number Publication Date
ES2952774T3 true ES2952774T3 (es) 2023-11-06

Family

ID=51177201

Family Applications (2)

Application Number Title Priority Date Filing Date
ES18202641T Active ES2952774T3 (es) 2013-06-21 2014-06-20 1,2,4-triazoles como moduladores del transporte nuclear y uso en el tratamiento de formas específicas de cáncer
ES14738998T Active ES2724275T3 (es) 2013-06-21 2014-06-20 1,2,4-triazoles como moduladores del transporte nuclear y usos de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES14738998T Active ES2724275T3 (es) 2013-06-21 2014-06-20 1,2,4-triazoles como moduladores del transporte nuclear y usos de los mismos

Country Status (28)

Country Link
US (5) US9738624B2 (enExample)
EP (2) EP3492455B1 (enExample)
JP (2) JP6730922B2 (enExample)
KR (2) KR102545732B1 (enExample)
CN (3) CN110386919B (enExample)
AU (5) AU2014284168B2 (enExample)
BR (1) BR112015032071B1 (enExample)
CA (1) CA2915365C (enExample)
CY (1) CY1122730T1 (enExample)
DK (2) DK3492455T3 (enExample)
EA (1) EA029743B1 (enExample)
ES (2) ES2952774T3 (enExample)
HR (1) HRP20190524T1 (enExample)
HU (1) HUE042800T2 (enExample)
IL (2) IL243099B (enExample)
LT (1) LT3010892T (enExample)
ME (1) ME03421B (enExample)
MX (1) MX365939B (enExample)
PL (1) PL3010892T3 (enExample)
PT (1) PT3010892T (enExample)
RS (1) RS58581B1 (enExample)
SG (1) SG11201510036TA (enExample)
SI (1) SI3010892T1 (enExample)
SM (1) SMT201900184T1 (enExample)
TR (1) TR201904455T4 (enExample)
UA (1) UA119238C2 (enExample)
WO (1) WO2014205389A1 (enExample)
ZA (1) ZA201509015B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2791914C (en) 2010-03-05 2019-01-15 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US9303000B2 (en) 2011-01-17 2016-04-05 Karyopharm Therapeutics Inc. Olefin containing nuclear transport modulators and uses thereof
SMT201800171T1 (it) 2011-07-29 2018-07-17 Karyopharm Therapeutics Inc Modulatori di trasporto nucleare contenenti idrazide e loro usi
KR102022715B1 (ko) 2011-07-29 2019-09-18 카리오팜 쎄라퓨틱스, 인코포레이티드 핵 수송 조절인자 및 이의 용도
MX364992B (es) 2012-05-09 2019-05-17 Biogen Ma Inc Moduladores del transporte nuclear y usos de los mismos.
WO2014144772A1 (en) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
US9738624B2 (en) 2013-06-21 2017-08-22 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
EP4112615A1 (en) 2014-08-15 2023-01-04 Karyopharm Therapeutics Inc. Compositions comprising one crystalline form of selinexor
MA43530A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
MA43529A (fr) * 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
WO2018050801A1 (en) * 2016-09-16 2018-03-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of systemic mastocytosis
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
RU2756512C1 (ru) 2018-01-10 2021-10-01 ЭксДабл-ЮФАРМА ЛТД. Пролекарства кетамина, его композиции и применения
WO2019232724A1 (en) * 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
WO2020051294A1 (en) * 2018-09-07 2020-03-12 Karyopharm Therapeutics Inc. The combination of xpo1 inhibitors and second agents for the treatment of prostate cancer
WO2020092965A1 (en) * 2018-11-01 2020-05-07 Karyopharm Therapeutics Inc. E2f1 as a biomarker for treatments using xpo1 inhibitors
US11518763B2 (en) 2018-12-05 2022-12-06 Scohia Pharma, Inc. Macrocyclic compound and use thereof
CN111606890A (zh) * 2019-02-26 2020-09-01 微境生物医药科技(上海)有限公司 含丙烯酰基的核转运调节剂及其用途
MX2021013211A (es) 2019-05-01 2022-03-11 Karyopharm Therapeutics Inc Proceso para la preparacion de inhibidores de xpo1 y productos intermedios para su uso en la preparacion de inhibidores de xpo1.
WO2021202745A1 (en) 2020-03-31 2021-10-07 Karyopharm Therapeutics Inc. Treatment of covid-19 with a sine compound
CN113880803B (zh) * 2020-07-03 2024-07-02 上海天慈国际药业有限公司 一种xpo-1抑制剂的制备方法
WO2022089629A1 (zh) * 2020-11-02 2022-05-05 江苏柯菲平医药股份有限公司 1,2,4-三氮唑衍生物及其制备方法和用途
CN112294819B (zh) * 2020-12-03 2021-12-14 中国人民解放军军事科学院军事医学研究院 一种炎症小体抑制剂及其应用
CN113045550A (zh) * 2021-03-12 2021-06-29 深圳济康医药科技有限公司 一种三氮唑类衍生物及其制备方法和应用
IL308647A (en) 2021-05-20 2024-01-01 Karyopharm Therapeutics Inc Methods for the synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms
CN113248474A (zh) * 2021-05-24 2021-08-13 王能能 五元氮唑杂环衍生物及其制备方法和用途
JP7737544B2 (ja) 2021-08-13 2025-09-10 エックスダブリューファーマ リミテッド ケタミン誘導体の医薬組成物及び経口剤形
CN117940409A (zh) * 2021-09-08 2024-04-26 南京明德新药研发有限公司 丙烯酰胺类化合物及其应用
EP4424676A4 (en) * 2021-10-29 2025-11-12 Chia Tai Tianqing Pharmaceutical Group Co Ltd Pyridyl-containing compound
WO2023134629A1 (zh) * 2022-01-12 2023-07-20 上海海雁医药科技有限公司 核转运调节剂及其用途
WO2024102477A1 (en) 2022-11-11 2024-05-16 Karyopharm Therapeutics Inc. Crystalline forms of eltanexor and process for preparing same
TWI863768B (zh) * 2023-12-21 2024-11-21 友達光電股份有限公司 顯示裝置

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR840000529A (ko) 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
CS229934B2 (en) 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
IL97249A (en) 1990-02-23 1995-01-24 Takeda Chemical Industries Ltd Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
JP3111321B2 (ja) 1990-02-23 2000-11-20 武田薬品工業株式会社 縮合チアゾール化合物
US5541213A (en) 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en) 1994-05-05 1995-11-21 Minnesota Mining And Manufacturing Company Mist suppressant for solvent extraction metal electrowinning
AU4368996A (en) 1994-11-23 1996-06-17 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
US20030018025A1 (en) 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
CA2229617A1 (en) 1995-10-20 1997-05-01 Dr. Karl Thomae Gmbh 5-membered heterocycles, medicaments containing these compounds, their use and processes for their preparation
EP1544197A1 (en) 1996-04-04 2005-06-22 Shionogi & Co., Ltd. Intermediates for cephem compounds
JP4054992B2 (ja) 1996-04-25 2008-03-05 日産化学工業株式会社 エチレン誘導体および有害生物防除剤
CN101817784B (zh) 1996-04-25 2012-02-01 日产化学工业株式会社 乙烯衍生物和含有该衍生物的杀有害生物剂
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US5994398A (en) 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja) 1997-12-19 2010-02-17 武田薬品工業株式会社 アニリド誘導体、その製造法および用途
WO1999050264A1 (en) 1998-03-30 1999-10-07 Kyowa Hakko Kogyo Co., Ltd. Quinazoline derivatives
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
US7569724B2 (en) 2000-09-29 2009-08-04 Topotarget Uk Limited Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
KR20100107509A (ko) 2001-09-14 2010-10-05 9222-9129 퀘벡 인코포레이티드 히스톤 데아세틸라아제의 억제제
WO2004037248A2 (en) 2002-10-24 2004-05-06 Carex Sa Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
JP4145230B2 (ja) 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
MXPA05004505A (es) 2002-11-01 2005-07-26 Takeda Pharmaceutical Agente para prevenir o tratar la neuropatia.
US7342115B2 (en) 2002-11-08 2008-03-11 Neurogen Corporation 3-substituted-6-aryl pyridines
WO2004076418A1 (en) 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
BRPI0511504A (pt) 2004-05-26 2008-01-22 Eisai R&D Man Co Ltd composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
MX2007001634A (es) 2004-08-11 2007-04-23 Kyorin Seiyaku Kk Nuevo derivado de acido amino benzoico ciclico.
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
EP1849465A4 (en) 2005-02-18 2008-12-24 Takeda Pharmaceutical AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR
USRE46792E1 (en) 2005-11-15 2018-04-17 Otsuka Pharmaceutical Co., Ltd. Oxazole compound and pharmaceutical composition
JP2007210929A (ja) 2006-02-09 2007-08-23 Sankyo Co Ltd ウレア化合物を含有する医薬
WO2007102580A1 (ja) 2006-03-09 2007-09-13 Eisai R & D Management Co., Ltd. 多環式シンナミド誘導体
CN101466670B (zh) 2006-04-07 2013-04-17 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
KR101507173B1 (ko) 2006-04-18 2015-03-30 닛뽕 케미파 가부시키가이샤 페록시좀 증식제 활성화 수용체 δ 의 활성화제
CN101443330B (zh) 2006-06-13 2012-12-19 上海海和药物研究开发有限公司 杂环非核苷类化合物及其制备方法、药物组合物和作为抗病毒抑制剂的用途
PL2054411T3 (pl) 2006-07-27 2015-02-27 Amorepacific Corp Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne
TWI386405B (zh) 2006-09-05 2013-02-21 咪唑衍生物
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
JP2010519337A (ja) 2007-02-26 2010-06-03 コーサン バイオサイエンシーズ， インコーポレイテッド カルバメート化合物
EP2003118A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Zimtsäurederivate als Modulatoren des EP2-Rezeptors
TW201011003A (en) 2008-08-08 2010-03-16 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 activity
JP2012532889A (ja) 2009-07-09 2012-12-20 クレッシェンド セラピューティクス、エルエルシー 創傷治療方法及び傷跡変性方法
US8518968B2 (en) 2009-12-04 2013-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hydrazone and diacyl hydrazine compounds and methods of use
CA2791914C (en) 2010-03-05 2019-01-15 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US9303000B2 (en) 2011-01-17 2016-04-05 Karyopharm Therapeutics Inc. Olefin containing nuclear transport modulators and uses thereof
KR102022715B1 (ko) 2011-07-29 2019-09-18 카리오팜 쎄라퓨틱스, 인코포레이티드 핵 수송 조절인자 및 이의 용도
SMT201800171T1 (it) 2011-07-29 2018-07-17 Karyopharm Therapeutics Inc Modulatori di trasporto nucleare contenenti idrazide e loro usi
WO2013020024A2 (en) 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
MX364992B (es) 2012-05-09 2019-05-17 Biogen Ma Inc Moduladores del transporte nuclear y usos de los mismos.
US20160016916A1 (en) 2013-03-15 2016-01-21 Karyopharm Therapeutics Inc. Exo Olefin-Containing Nuclear Transport Modulators and Uses Thereof
WO2014144772A1 (en) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US9738624B2 (en) 2013-06-21 2017-08-22 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11567063B2 (en) 2013-11-15 2023-01-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods for assessing cell viability or predicting cell response to a treatment using cell movement
EP3172214B1 (en) 2014-07-26 2020-05-13 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
EP4112615A1 (en) 2014-08-15 2023-01-04 Karyopharm Therapeutics Inc. Compositions comprising one crystalline form of selinexor
MA43530A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
MA43529A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
WO2017118940A1 (en) 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
WO2018129227A1 (en) 2017-01-05 2018-07-12 Watson Laboratories Inc. Novel crystalline forms of selinexor and process for their preparation
EP3808742A1 (en) 2019-10-16 2021-04-21 Sandoz AG Polymorph of selinexor
WO2021111103A1 (en) 2019-12-06 2021-06-10 Bae Systems Plc Light source
WO2022087218A1 (en) 2020-10-21 2022-04-28 Karyopharm Therapeutics Inc. Crystalline form of selinexor

Also Published As

Publication number Publication date
HUE042800T2 (hu) 2019-07-29
WO2014205389A8 (en) 2015-04-02
AU2022283662A1 (en) 2023-02-02
BR112015032071B1 (pt) 2022-06-14
CA2915365A1 (en) 2014-12-24
US11124493B2 (en) 2021-09-21
US9738624B2 (en) 2017-08-22
EP3010892A1 (en) 2016-04-27
RS58581B1 (sr) 2019-05-31
KR102322794B1 (ko) 2021-11-05
CN110386919A (zh) 2019-10-29
DK3492455T3 (da) 2023-08-14
AU2019200147A1 (en) 2019-01-31
PL3010892T3 (pl) 2019-07-31
AU2020277088A1 (en) 2020-12-24
ES2724275T3 (es) 2019-09-09
CY1122730T1 (el) 2021-03-12
SMT201900184T1 (it) 2019-05-10
NZ714931A (en) 2021-02-26
HRP20190524T1 (hr) 2019-05-17
JP6730922B2 (ja) 2020-07-29
AU2020277088B2 (en) 2022-09-08
AU2014284168B2 (en) 2018-10-25
CN110183422A (zh) 2019-08-30
TR201904455T4 (tr) 2019-04-22
LT3010892T (lt) 2019-04-10
CN110183422B (zh) 2023-07-14
KR20210137223A (ko) 2021-11-17
EP3492455A1 (en) 2019-06-05
SI3010892T1 (sl) 2019-05-31
PT3010892T (pt) 2019-04-12
WO2014205389A1 (en) 2014-12-24
KR102545732B1 (ko) 2023-06-20
US20200199099A1 (en) 2020-06-25
CN105339358A (zh) 2016-02-17
US20180155317A1 (en) 2018-06-07
CN110386919B (zh) 2023-07-14
IL261612A (en) 2018-10-31
CA2915365C (en) 2022-08-16
MX2015016983A (es) 2016-07-21
CN105339358B (zh) 2019-06-04
ZA201509015B (en) 2018-07-25
MX365939B (es) 2019-06-19
DK3010892T3 (en) 2019-04-15
BR112015032071A2 (pt) 2017-07-25
AU2014284168A1 (en) 2015-12-24
EP3492455B1 (en) 2023-05-17
US20250059158A1 (en) 2025-02-20
EP3010892B8 (en) 2019-05-22
EA029743B1 (ru) 2018-05-31
US20220177445A1 (en) 2022-06-09
US10407405B2 (en) 2019-09-10
EP3010892B1 (en) 2018-12-26
US11945794B2 (en) 2024-04-02
KR20160029076A (ko) 2016-03-14
JP7061161B2 (ja) 2022-04-27
SG11201510036TA (en) 2016-01-28
US20160152596A1 (en) 2016-06-02
AU2024204818A1 (en) 2024-08-01
IL243099A0 (en) 2016-02-01
UA119238C2 (uk) 2019-05-27
HK1223936A1 (en) 2017-08-11
EA201690044A1 (ru) 2016-05-31
JP2016522266A (ja) 2016-07-28
IL243099B (en) 2020-09-30
ME03421B (me) 2020-01-20
JP2020172527A (ja) 2020-10-22

Similar Documents

Publication Publication Date Title
ES2952774T3 (es) 1,2,4-triazoles como moduladores del transporte nuclear y uso en el tratamiento de formas específicas de cáncer
US10709706B2 (en) Nuclear transport modulators and uses thereof
HK40009479B (en) 1,2,4-triazoles as nuclear transport modulators and use in the treatment of specific forms of cancer
HK40009479A (en) 1,2,4-triazoles as nuclear transport modulators and use in the treatment of specific forms of cancer
HK1223936B (en) 1,2,4-triazoles as nuclear transport modulators and uses thereof
NZ714931B2 (en) Nuclear transport modulators and uses thereof